BTK

Cat. No.

A34462

CAS No.

2922723-28-0

Topoisomerase I inhibitor 11

Topoisomerase I inhibitor 11 is a potent inhibitor of Topoisomerase I, a key enzyme involved in DNA replication and repair. This compound disrupts the enzyme's catalytic activity, leading to the accumulation of DNA damage and ultimately inducing apoptosis in cancer cells. Topoisomerase I inhibitor 11 is primarily utilized in cancer research, particularly for studying mechanisms of drug resistance and the therapeutic potential of targeting Topoisomerase I in various malignancies.

Cat. No.

A34464

CAS No.

1609465-88-4

(Rac)-PF-06250112

(Rac)-PF-06250112 is a racemic mixture of PF-06250112, a highly selective and orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK). This compound demonstrates potent inhibitory activity against BTK as well as BMX nonreceptor tyrosine kinase and TEC. Its selectivity and efficacy make it a valuable tool for research applications focused on B cell malignancies and other diseases associated with aberrant BTK signaling.

Cat. No.

A34466

CAS No.

2824922-28-1

BTK-IN-8

BTK-IN-8 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), exhibiting a binding affinity with an IC50 of 0.22 nM and a Kd of 0.91 nM. This compound demonstrates significant cellular activity against whole blood CD69, with an IC50 of 0.029 µM. BTK-IN-8 is primarily used in research focused on hematological malignancies and autoimmune disorders, providing insights into BTK-mediated signaling pathways.

Cat. No.

A34468

CAS No.

1423129-83-2

RN983

RN983 is a highly selective inhibitor of Bruton's tyrosine kinase (Btk), demonstrating potent inhibition of immunoglobulin G (IgG) production in B-cells with an IC50 of 2.5 nM, and prostaglandin D2 (PGD2) production in mast cells with an IC50 of 8.3 nM. This compound serves as a valuable tool for investigating the roles of Btk in B-cell signaling and mast cell activation, making it relevant in the study of asthma and other allergic diseases.

Cat. No.

A34469

CAS No.

2502301-31-5

BTK-IN-36

BTK-IN-36 is a potent Bruton’s Tyrosine Kinase (BTK) inhibitor, exhibiting an IC50 of 0.5 nM. This compound effectively inhibits BTK signaling pathways, which are crucial for B-cell receptor signaling and have implications in various cancers. BTK-IN-36 is applicable in cancer research, particularly in studies exploring targeted therapies for B-cell malignancies.

Cat. No.

A34470

CAS No.

2755843-62-8

RET-IN-14

RET-IN-14 is a highly selective RET inhibitor that demonstrates potent inhibition with IC50 values of less than 0.51 nM for wild-type RET and varying nanomolar activity against RET mutations (G810R and V804M) as well as BTK and its C481S mutant. Its exceptional efficacy positions RET-IN-14 as a valuable tool for investigating RET-driven tumors and exploring therapeutic strategies in cancer research.

Cat. No.

A34471

CAS No.

2820426-92-2

BTK-IN-15

BTK-IN-15 is a highly potent inhibitor of Bruton's tyrosine kinase (BTK), exhibiting an IC50 value of 0.7 nM. This compound demonstrates exceptional selectivity for BTK and displays significant antitumor activity. Additionally, BTK-IN-15 is known to induce apoptosis, making it a valuable tool for research in cancer biology and the development of targeted therapies.

Cat. No.

A34472

CAS No.

2088001-24-3

VA5

VA5 is a potent Bruton’s tyrosine kinase (BTK) inhibitor, designed to selectively inhibit BTK activity. This compound plays a crucial role in modulating B-cell signaling pathways and has potential applications in studying various diseases associated with dysregulated BTK activity, including certain hematological malignancies and autoimmune disorders. VA5 serves as a valuable tool in preclinical research to further investigate the therapeutic potential of targeting BTK.

Cat. No.

A34474

CAS No.

2758410-51-2

BTK-IN-38

BTK-IN-38 is a potent inhibitor of Bruton's tyrosine kinase (BTK). It effectively inhibits the proliferation of DOHH2 and BT474 cancer cell lines, exhibiting IC50 values of 114 nM and 340 nM, respectively. This compound is of particular interest in research applications targeting B-cell malignancies and related signaling pathways.

Cat. No.

A34476

CAS No.

2573048-11-8

BTK-IN-23

BTK-IN-23 is a selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 of 12.8 nM. This compound also exhibits inhibitory effects on BMX and BLK, with IC50 values of 5.7 nM and 35.6 nM, respectively. BTK-IN-23 demonstrates enhanced kinase selectivity compared to Ibrutinib, making it a valuable tool for research in cancer and autoimmune disease therapies, particularly in studies focusing on B-cell signaling pathways.

Cat. No.

A34477

CAS No.

3081685-04-0

BTK-IN-43

BTK-IN-43 is a selective inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 value of 21.6 nM. This compound is capable of oral administration and exhibits potent activity against BTK-mediated signaling pathways. It is primarily utilized in research applications focused on hematological malignancies and immune disorders driven by aberrant BTK activity.

Cat. No.

A34479

CAS No.

2041789-14-2

HZ-A-005

HZ-A-005 is a potent and selective covalent inhibitor of Bruton’s tyrosine kinase (BTK), a critical regulator in B cell receptor signaling. This compound demonstrates significant anti-tumor activity, effectively reducing tumor growth in xenograft mouse models. HZ-A-005 is valuable for research applications focused on B cell malignancies and the study of BTK's role in various signaling pathways.

Cat. No.

A34480

CAS No.

1015441-29-8

BTK-IN-32

BTK-IN-32 is a selective Bruton’s tyrosine kinase (BTK) inhibitor that effectively modulates BTK activity. It uniquely activates both full-length BTK and smaller multidomain fragments, rather than solely targeting the isolated kinase domain. This compound is useful in research applications focused on B-cell signaling pathways and the development of therapies for related hematological malignancies.

Cat. No.

A34482

CAS No.

2696450-27-6

BTK inhibitor 20

BTK Inhibitor 20 is a highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK), exhibiting an IC50 value of 8 nM. This compound effectively modulates the BTK signaling pathway, playing a critical role in B-cell receptor signaling and related processes. It is valuable for research focused on B-cell malignancies, autoimmune diseases, and other conditions where BTK activity is implicated.

Cat. No.

A34483

CAS No.

2562351-92-0

BTK-IN-25

BTK-IN-25 is a highly potent inhibitor of Bruton’s tyrosine kinase (BTK), demonstrating an IC50 of 0.77 nM against the BTK(C481S) mutant and 1 nM in DOHH2 cells. This compound is valuable for exploring BTK-related signaling pathways and potential therapeutic interventions in B-cell malignancies. Its selective inhibition of BTK makes it a useful tool for research applications focused on the modulation of immune responses and the development of targeted cancer therapies.

Cat. No.

A34484

CAS No.

2762043-53-6

BTK-IN-12

BTK-IN-12 is a potent Bruton’s Tyrosine Kinase (BTK) inhibitor, with IC50 values of 1.2 nM for wild-type BTK and 0.8 nM for the mutated BTK (C481S). This compound selectively targets BTK, a key regulator in B-cell receptor signaling, making it valuable for research in hematological malignancies and autoimmune disorders. BTK-IN-12 can facilitate the study of therapeutic approaches for conditions associated with dysregulated B-cell activity.

Cat. No.

A34485

CAS No.

2792171-84-5

ABBV-992

ABBV-992 is a potent and selective Bruton's Tyrosine Kinase (BTK) inhibitor. It demonstrates significant inhibitory activity, making it a valuable tool for studying various hematological malignancies. This compound is primarily utilized in cancer research to investigate BTK signaling pathways and their roles in tumor progression and survival.

Cat. No.

A34488

CAS No.

1952316-43-6

(R)-Acalabrutinib

Synonyms: (R)-ACP-196

(R)-Acalabrutinib is a specific inhibitor of Bruton’s tyrosine kinase (BTK), a critical protein involved in B-cell receptor signaling. This compound serves as a valuable tool for research applications in hematological malignancies, particularly in the study of B-cell functions and the development of targeted therapies for conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Its high selectivity for BTK allows for detailed investigations into BTK-mediated pathways and potential therapeutic interventions.

Cat. No.

A34489

CAS No.

1374240-01-3

BTK-IN-19

BTK-IN-19 is a reversible Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of less than 0.001 μM. This compound demonstrates potent inhibitory activity against BTK, making it a valuable tool for studying B-cell signaling pathways. BTK-IN-19 is applicable in research focused on various hematological malignancies and autoimmune diseases, contributing to the understanding of therapeutic strategies targeting BTK.

Cat. No.

A34490

CAS No.

2883232-92-4

BTK-IN-16

BTK-IN-16 is a dual inhibitor targeting Bruton’s tyrosine kinase (BTK), specifically effective against both wild type and the C481S mutant, with IC50 values of 5.1 μM and 4.1 μM, respectively. This compound is crucial for research into autoimmune diseases and chronic lymphocytic leukemia, where BTK plays a significant role in disease progression. Its ability to inhibit both forms of BTK makes BTK-IN-16 a valuable tool for studying therapeutic strategies in these conditions.

Cat. No.

A34492

CAS No.

1226872-27-0

BTK-IN-3

BTK-IN-3 is a selective inhibitor of Bruton's tyrosine kinase (BTK), a critical component in B-cell receptor signaling. This compound demonstrates significant biological activity by inhibiting BTK-mediated pathways, which are often implicated in various hematological malignancies. BTK-IN-3 is therefore utilized in research applications focused on cancer biology, particularly in the investigation of B-cell cancers and autoimmune disorders.

Cat. No.

A34494

CAS No.

2031255-23-7

Ibrutinib dimer

Ibrutinib dimer is a dimeric form of Ibrutinib, a selective and irreversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 0.5 nM. This compound serves as a valuable tool for studying Btk-mediated signaling pathways and its implications in various hematological malignancies. Researchers can utilize Ibrutinib dimer to investigate the effects of Btk inhibition in cellular models and to explore its potential therapeutic applications in cancer research.

Cat. No.

A34495

CAS No.

1807619-60-8

(Rac)-IBT6A hydrochloride

(Rac)-IBT6A hydrochloride is a racemic mixture of IBT6A, a byproduct of Ibrutinib. This compound acts as a selective, irreversible Bruton's tyrosine kinase (Btk) inhibitor with an IC50 of 0.5 nM, making it useful for studying Btk-mediated signaling pathways. It serves as a valuable reagent in the synthesis of Ibrutinib derivatives and adducts, facilitating research into therapeutic strategies for diseases such as B-cell malignancies.

Cat. No.

A34498

CAS No.

2662512-14-1

(R,R)-Birelentinib

Synonyms: (R,R)-DZD8586

(R,R)-Birelentinib is a potent Bruton's tyrosine kinase (BTK) inhibitor, achieving IC50 values of 0.7 nM for wild-type BTK and 0.86 nM for the C481S mutant. This compound effectively inhibits the self-phosphorylation of BTK, with an IC50 of 24.3 nM. (R,R)-Birelentinib demonstrates significant anti-proliferative effects against wild-type and C481S mutant HEK293 cells, making it valuable for research into drug-resistant B-cell malignancies.

Cat. No.

A34500

CAS No.

845269-74-1

CGI 560

CGI 560 is a potent inhibitor of Bruton's tyrosine kinase (BTK), exhibiting an IC50 value of 400 nM. This compound plays a significant role in the modulation of B-cell receptor signaling pathways, making it a valuable tool for research in hematological malignancies and autoimmune diseases. Its ability to selectively inhibit BTK can aid in elucidating the mechanistic underpinnings of various B-cell-related disorders.